Hemostatics is developing a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling hemorrhagic conditions.
Hemostatics has raised $1.1M in total funding. The most recent round was Grant. The last funding was announced in January 2024.
Hemostatics is headquartered in Barcelona, Spain.
Hemostatics is developing a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling hemorrhagic conditions.
Hemostatics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hemostatics — Funding & Investors." VCBacked, January 1, 2024, https://www.vcbacked.co/company/hemostatics. Accessed August 14, 2026.
VCBacked. (2024). Hemostatics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/hemostatics
{{cite web |title=Hemostatics — Funding & Investors |url=https://www.vcbacked.co/company/hemostatics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated